Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...

Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

In a notable move, Hims & Hers Health donated $1 million to President-elect Donald Trump’s inauguration fund, signaling its ...

Biomea Fusion (BMEA) announce compelling results from in vivo studies of icovamenib in combination with semaglutide. Highlights of the Study: ...

Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...